McKesson Corp.

McKesson provides pharmaceuticals and medical supplies and services to its customers. The company's segments include: U.S. Pharmaceutical and Specialty Solutions, which provides distribution and logistics services for branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs and other healthcare-related products to customers; European Pharmaceutical Solutions, which provides distribution and services to wholesale, institutional and retail customers in European countries where it owns, partners or franchises with retail pharmacies; and Medical-Surgical Solutions, which delivers medical-supply distribution, logistics, biomedical and other services to healthcare providers.
  • TickerMCK
  • ISINUS58155Q1031
  • ExchangeNew York Stock Exchange
  • SectorFood & Drug Retailers
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

Moody's announces completion of a periodic review of ratings of McKesson Corporation

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of McKesson Corporation. Global Credit Research- 17 May 2019. New York, May 17, 2019-- Moody's Investors Service has completed a periodic review of the ratings of McKesson Corporation and other ratings that are associated with the same analytical unit.

McKesson Corporation - December 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's assigns Baa2 to McKesson's new senior unsecured notes

Moody's Investors Service (Moody's) assigned a Baa2 rating to McKesson Corporation's ("McKesson") new note offerings. All of McKesson's existing note and short term ratings remain unchanged. The company's rating outlook remains stable. Moody's expects that McKesson will use the proceed...

McKesson Corporation - September 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

McKesson Corporation: Update to credit analysis

McKesson will continue to be an industry leader, with significant scale and a moderate financial leverage profile.

Valens Research

Valens Equity Insights and Inflections - 2019 05 29

SSNC currently trades above historical averages relative to UAFRS-based (Uniform) Earnings, with a 19.4x Uniform P/E. Even at these levels, the market is pricing in expectations for Uniform ROA to decline from 70% in 2018 to 24% in 2023, accompanied by 27% Uniform Asset growth going forward. However, analysts have less bearish expectations, projecting Uniform ROA to only decline to 57% by 2020, accompanied by 24% Uniform Asset growth. Meanwhile, management is confident in their focus on core margins, and new and existing business wins. Should SSNC just meet analyst expectations, as positive ma...

Valens Research

MCK- Embedded Expectations Analysis - 2019 05 24

McKesson Corporation (MCK:USA) currently trades below historical averages relative to UAFRS-based (Uniform) Earnings, with an 11.9x Uniform P/E, implying bearish expectations for the firm. Moreover, management has concerns about their efficiency initiatives, U.K. business performance, and their ability to meet earnings guidance. Specifically, management may be exaggerating the success of their efficiency initiatives and the demand for patient home delivery. Also, they may lack confidence in their ability to sustain continuing operations and net income growth and to improve their European Phar...

Soo Romanoff

Morningstar | McKesson Has Decent Quarter Despite International Headwinds; No Change to Our Thinking

McKesson reported mixed quarterly results, with lighter-than-expected revenue yet better-than-expected earnings. As we have heard consistently on earnings calls from companies under our coverage, generic drug pricing appears to have stabilized and branded inflation rates were in the midsingle digits as expected, which implies that volumes were likely softer than expected. Strong cost controls and share repurchases drove EPS upside relative to our expectations. Shares were up 5% intraday based on results but remain 15% below the 52-week high of $152. We maintain our narrow moat rating and fair ...

Soo Romanoff

McKesson Has Decent Quarter Despite International Headwinds; No Change to Our Thinking

McKesson reported mixed quarterly results, with lighter-than-expected revenue yet better-than-expected earnings. As we have heard consistently on earnings calls from companies under our coverage, generic drug pricing appears to have stabilized and branded inflation rates were in the midsingle digits as expected, which implies that volumes were likely softer than expected. Strong cost controls and share repurchases drove EPS upside relative to our expectations. Shares were up 5% intraday based on...

1 director sold

A director at Mckesson Corp sold 1,350 shares at 128.690USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

ValuEngine Rating and Forecast Report for MCK

MarketLine Department

PharMerica Corporation - Strategy, SWOT and Corporate Finance Report

PharMerica Corporation - Strategy, SWOT and Corporate Finance Report Summary PharMerica Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights PharMerica Corporation (PharMerica or 'the company') is a pharmacy management services provider for skilled nursing facilities (SNF), long term care facilities (LTC), assisted living facilities (ALF), hospitals and ...

MarketLine Department

Allergan plc - Strategy, SWOT and Corporate Finance Report

Allergan plc - Strategy, SWOT and Corporate Finance Report Summary Allergan plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Allergan plc (Allergan or 'the company') is a pharmaceutical company that develops, manufactures and markets branded pharmaceutical products, biologic, device, surgical and regenerative medicine products. The company offers products in...

MarketLine Department

Allergan plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Allergan plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Allergan plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlight...

MarketLine Department

TELUS Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's TELUS Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by TELUS Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key...

MarketLine Department

Allscripts Healthcare Solutions, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Allscripts Healthcare Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Allscripts Healthcare Solutions, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization t...

Dave Nicoski ...
  • John Betz

Vermilion Int'l Compass: Global Equity Strategy

Big-picture technicals offer a compelling outlook for equities -- in the long-run. Despite arguably stretched trends, especially in the U.S. and EM, one indicator in particular keeps us optimistic: monthly charts. What is likely the least-used timeframe, monthly charts (> 20 years) offer the most clarity. And what's clear right now is: (1) Europe is on the doorstep of breaking above secular resistance; (2) Japan is breaking out above secular resistance; (3) and EM already has. Speaking of EM, we view this as the place to be, or overweight, in 2018. The EM/EAFE's 20-year chart (below) reveals ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch